 | Up a level |
Tosco, L; Laenen, A; Briganti, A; Gontero, P; Karnes, R J; Albersen, M; Bastian, P J; Chlosta, P; Claessens, F; Chun, F K; Everaerts, W; Gratzke, C; Graefen, M; Kneitz, B; Marchioro, G; Salas, R S; Tombal, B; Van den Broeck, T; Moris, L; Battaglia, A; ... (2017). The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. Prostate cancer and prostatic diseases, 20(4), pp. 407-412. Nature 10.1038/pcan.2017.29
Sivaraman, A; Ordaz Jurado, G; Cathelineau, X; Barret, Eric; Dell'Oglio, P; Joniau, S; Bianchi, M; Briganti, A; Spahn, Martin; Bastian, P; Chun, J; Chlosta, P; Gontero, P; Graefen, M; Jeffrey Karnes, R; Marchioro, G; Tombal, B; Tosco, L; van der Poel, H Henk and Sanchez-Salas, R (2016). Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. World journal of urology, 34(10), pp. 1367-1372. Springer 10.1007/s00345-016-1784-8
Moltzahn, Felix Roman; Karnes, J; Gontero, P; Kneitz, B; Tombal, B; Bader, P; Briganti, A; Montorsi, F; Van Poppel, H; Joniau, S; Spahn, Martin (2015). Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. Prostate cancer and prostatic diseases, 18(1), pp. 31-37. Nature 10.1038/pcan.2014.41
